Recce Pharmaceuticals Ltd. · SWB:R9Q

Recce Pharmaceuticals Ltd. financial statements

Recce Pharmaceuticals Ltd.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue7.51M5.03M4.37M3.08M1.64M1.12M679.6K1.29M139.3K
Cost of revenue356.4K10.4M7.22M217.2K187.7K295.6K200.8K56.1K53.1K25.5K
Gross profit-356.4K-2.94M-2.19M4.15M2.90M1.34M920.9K623.5K1.24M113.8K
Research and development10.2M7.04M7.17M6.22M5.56M1.99M416.4K372.2K999.4K
Selling, general and administrative8.68M8.46M5.87M4.11M2.37M6.81M1.75M1.60M1.34M1.54M
Operating income-23.2M-22.9M-22.1M-17.3M-14.2M-15.4M-5.41M-3.42M-2.92M-3.18M
Depreciation and amortization356.4K356.2K366.8K217.2K187.7K295.6K200.8K56.1K53.1K25.5K
EBITDA-22.8M-22.5M-21.7M-17.1M-14.0M-15.1M-5.21M-3.36M-2.87M-3.16M
Interest expense1.66M1.26M846.9K183.3K11.9K12.1K56.4K56.7K54.3K2.41K
Income before tax-23.8M-21.4M-22.6M-17.4M-14.1M-15.1M-5.39M-3.47M-2.96M-3.16M
Income tax-8.88M-6.74M-4.91M-4.31M-3.08M-1.57M-1.07M-679.6K-1.29M-139.3K
Net income-15.0M-21.4M-17.7M-13.1M-11.0M-13.5M-4.32M-2.79M-1.67M-3.03M
Earnings per share, basic-0.05-0.09-0.10-0.07-0.06-0.09-0.03-0.03-0.02-0.04

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents2.69M10.4M4.42M1.56M11.6M20.9M2.68M403.4K679.7K1.09M
Short-term investments236.6K207.9K47.0K20.1K0
Receivables3.87M435.3K159.4K90.7K582.7K245.5K41.4K36.5K21.0K60.2K
Inventory135.4K-36.5K-21.0K-60.2K
Current assets7.12M11.4M5.14M1.95M12.2M21.2M2.74M453.1K708.5K1.15M
Property, plant and equipment1.03M1.23M608.4K438.7K500.6K504.7K469.1K435.2K310.6K
Total assets8.53M12.4M6.37M2.56M12.6M21.7M3.24M922.2K1.14M1.46M
Accounts payable8.20M2.18M3.97M948.9K481.4K487.3K159.5K124.4K125.4K255.4K
Current liabilities16.3M6.13M15.1M4.85M2.45M1.08M885.2K1.27M416.4K690.3K
Long-term debt8.30M8.60M0161.3K
Total debt10.4M10.8M811.2K250.6K74.8K126.9K83.2K737.4K2.86K322.6K
Total liabilities25.3M15.5M15.9M5.14M2.56M1.18M931.5K1.33M448.8K874.4K
Shareholders' equity-16.7M-3.05M-9.52M-2.59M10.1M20.5M2.31M-405.6K694.9K590.1K
Shares outstanding289.2M237.0M177.1M175.7M175.9M157.0M128.5M95.4M85.6M77.4M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-9.89M-20.4M-13.0M-12.7M-9.01M-7.86M-3.81M-2.61M-1.73M-2.50M
Capital spending-62.0K-26.3K-141.9K-38.6K-40.3K-76.0K-5.94K-89.9K-177.8K-246.1K
Free cash flow-9.95M-20.5M-13.2M-12.7M-9.05M-7.93M-3.81M-2.70M-1.91M-2.74M
Cash from investing123.6K-443.9K-141.9K-38.6K-40.3K-76.0K-5.94K-89.9K-177.8K-246.1K
Cash from financing2.01M26.9M16.0M2.71M-240.5K26.1M6.09M2.43M1.50M243.0K
Dividends paid-1.72M-1.72M-1.72M0
Share buybacks102.0K-1.72M-1.72M-1.72M1.69M1.45M0
Change in cash-7.75M6.03M2.85M-10.0M-9.29M18.2M2.28M-276.3K-410.7K-2.50M